Neuronetics (STIM) PT Lowered to $4 at Canaccord Genuity
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts STIM Hot Sheet
Price: $2.71 +19.91%
Rating Summary:
5 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Rating Summary:
5 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
Canaccord Genuity analyst William Plovanic lowered the price target on Neuronetics (NASDAQ: STIM) to $4.00 (from $5.00) while maintaining a Buy rating.
You May Also Be Interested In
- Neuronetics (STIM) Tops Q3 EPS by 7c
- Insulet Corporation (PODD) PT Raised to $200 at Jefferies
- Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
